< View all leaders

Shehnaaz Suliman, M.D. (MB ChB), M.B.A., M.Phil.

Biotechnology Executive

Linkedin Icon Pink View Profile

Dr. Suliman has served as a member of the Ultragenyx board since February 2019. Dr. Suliman currently serves as chief executive officer of ReCode Therapeutics, a privately-held genetic medicines company. Previously Dr. Suliman was president and COO of Alector, an immuno-neurology company focused on neurodegenerative diseases. Dr. Suliman has held executive management and leadership roles at Theravance Biopharma, Inc., Genentech, Inc., Roche and Gilead Sciences, Inc. in business development, R&D portfolio management and operations and strategy in the past decade. Prior to Gilead, Dr. Suliman was an investment banker advising public and private companies on buy- and sell-side transactions.

Dr. Suliman received her M.D. (MB, ChB) at the University of Cape Town Medical School, South Africa, and holds an M.B.A., with distinction and M.Phil. in Development Studies degrees from Oxford University, where she was a Rhodes Scholar. Dr. Suliman serves as the chair of Executive Women in Bio and serves on the board of directors for life science technology company 10x Genomics (NASDAQ: TXG).